UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2014

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Massachusetts (State or other jurisdiction of incorporation) 000-21615 (Commission File Number) 04-2652826 (IRS Employer Identification No.)

14 Norfolk Avenue South Easton, Massachusetts 02375

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

The Company presented at the FSXinterlinked Investor Conference on October 29, 2014. The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 8.01 as if fully set forth herein.

The information contained in this Current Report, including Exhibit 99.1 are being furnished and not filed pursuant to this Item 8.01 of Form 8-K. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) l	Exhibits
-------	----------

Exhibit No.	Description
99.1	Company information - "Power Point Presentation" dated October 29, 2014 (filed herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRESSURE BIOSCIENCES, INC.

By: /s/ Richard T. Schumacher

Richard T. Schumacher President and Chief Executive Officer

3

Date: October 31, 2014

Investor Presentation

Pressure BioSciences, Inc. (OTCQB: PBIO)

Discovery Starts with Sample Preparation™

FSXinterlinked Investor Conference Dove Mountain, AZ October 29-31, 2014



Richard T. Schumacher President, CEO

Forward Looking Statements

This presentation may contain forward looking statements that reflect management's current views and opinions as to the status of the Company's products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company's filings with the Securities and Exchange Commission.




Company Overview (OTCQB: PBIO)







PBI

Primary Sample Preparation for Biomolecular Analysis: Cell Lysis



Value Proposition: PCT-based biological sample preparation





Selected Marquee Customers (150)



PCT Focus Area: Biomarker Discovery & Forensics

Biomarker Discovery: Cancer, Heart Disease, Stroke, Inf. Diseases, Etc.

- Dr. Andreas Huhmer Thermo Fisher Scientific
- Dr. Michael Alterman Tumor Vaccines and Biotechnology Branch, CBER, FDA
- Dr. Alexander Ivanov Harvard School of Public Health
- Dr. Jennifer Van Eyk, Johns Hopkins School of Medicine
- Dr. Wayne Hubbell, Distinguished Professor, Dept. of Chemistry & Biochemistry, UCLA
- Dr. Hans Robert Kalbitzer, Professor, University of Regensburg
- Dr. Ruedi Aebersold, Institute of Molecular Systems Biology, ETH Zurich, Switzerland

Forensics: Improved Processing of Rape Kits, Enhanced DNA Detection


- Dr. Bruce Budowle, Health Science Center, University of North Texas
- Dr. Bruce McCord, Florida International University
- Dr. Dr. Henry C. Lee, the Henry C. Lee Institute of Forensic Science



PCT Sample Preparation System



Barocycler™ NEP2320



Barocycler™ NEP3229



PULSE Tube



MicroTubes

PBI








PCT-dependent Kits

The Barrier

Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities.



The Solution (4 years in the making)



June 2014 Release ASMS Annual Meeting

Initial Shipment Expected October 2014

- Initial Application:
 - High pressure digestion
- Consumable:
 - Proprietary 8-well strips
- Number of Samples:
 - 48 samples
- User Control:
 - Easy to use touch screen
 - LabView Software

The Future (is now)



Professor Wayne L. Hubbell



Prof Wayne Hubbell



Dr. Jennifer Van Eyk



Mr. David Weild

PBI

- Distinguished Prof: UCLA School of Medicine
- Member, Nat'l Academy of Sciences
- Gold Medal, International EPR Society
- Research: Structure & Function Proteins
- Prof of Medicine, Cedars-Sinai Med. Ctr.
- Director, Barbara Streisand Women's HC
- Director, NHLBI Prot Innov Ctr, Heart Failure
- Formerly Prof of Medicine, J. Hopkins SoM
- Research: Mechanisms Heart Disease
- Founder, Chairman, CEO: IssuWorks
- Former Vice-Chairman of NASDAQ
- Former Head, Global Equity Trnx, Prud SEC
- Former President, PrudSecurities.com
- Known as "Father of the JOBS Act"

Recent News

	Sept 19 th	Completion of the 1 st Phase of Barozyme HT48 Commercialization Plan – first install expected in Oct 2014	
	Oct 1 st	PBI Invited to Speak at Warsaw Stock Exchange. \$100B (US) Available Through Grants. Non-dilutive.	
	Oct 20 th	Announced Partnership with Powertech Technology Company to Develop China Market for PBI's PCT Platform	
	Oct 27 th	Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 Hours Presented	
π	Prof. Ruedi Aebersold said: "working with AB SCIEX we developed a new and improved mass spectrometry method called SWATH, which when combined with PCT and consumables (including the u-Pestle) resulted in significantly improved protein data from needle biopsy samples. We believe PCT SWATH will lead to better analysis of needle biopsy samples in both clinical and research settings, leading to advances in personalized medicine, especially cancer diagnosis and treatment."		
FDI		22	

